Multiple Myeloma Clinical Trials
Multiple Myeloma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for multiple Myeloma. Corterve aggregates actively recruiting Multiple Myeloma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Multiple Myeloma studies
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationNCT05243797PHASE3European Myeloma Network B.V.Multiple MyelomaPhoenix, Arizona
- Tissue Collection for Studies of Lymph CancerNCT01676805National Cancer Institute (NCI)Hodgkin DiseaseBethesda, Maryland
- Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple MyelomaNCT07236502NAMedical College of WisconsinMultiple Myeloma (MM)Maywood, Illinois
- Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06297226PHASE2Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyMultiple MyelomaBirmingham, Alabama
- An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersNCT07226934NAWashington University School of MedicineLymphomaSt Louis, Missouri
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaNCT05730036PHASE3Regeneron PharmaceuticalsRelapsed Refractory Multiple Myeloma (RRMM)Los Angeles, California
- A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)NCT07393282PHASE3Regeneron PharmaceuticalsHigh Risk Smoldering Multiple Myeloma (HR-SMM)Phoenix, Arizona
- AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)NCT05850234PHASE1, PHASE2AstraZenecaRelapsed/Refractory Multiple MyelomaBirmingham, Alabama
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseNCT06948084PHASE2National Cancer Institute (NCI)Recurrent Multiple MyelomaCoeur d'Alene, Idaho
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)NCT07222761PHASE3Regeneron PharmaceuticalsRelapsed and/or Refractory Multiple Myeloma (RRMM)Atlanta, Georgia
- Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaNCT07657312PHASE2Naresh BummaCytokine Release SyndromeColumbus, Ohio
- Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMNCT06518551PHASE1, PHASE2Omar Nadeem, MDMyelomaBoston, Massachusetts
Multiple Myeloma trials by state
Multiple Myeloma trials by metro
Frequently asked questions
- How do I find recruiting Multiple Myeloma clinical trials?
- Browse the actively recruiting Multiple Myeloma studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Multiple Myeloma clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Multiple Myeloma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.